Navigation Links
No Risks to Pregnancy Seen With Morning Sickness Drug

By Amy Norton
HealthDay Reporter

WEDNESDAY, Feb. 27 (HealthDay News) -- A drug commonly used to treat severe cases of morning sickness does not appear to be linked to birth defects or other risks to the baby, a large new study suggests.

The Danish researchers said the findings, reported in the Feb. 28 issue of the New England Journal of Medicine, do not prove the medication is risk-free. But they said the study should reassure women who need the drug, called ondansetron (Zofran and generics).

"We can never say it's 100 percent safe," said Christina Chambers, co-director of the Center for Promotion of Maternal Health and Infant Development at the University of California, San Diego.

"But this is a good study that really adds to what we've known," said Chambers, who was not involved in the work.

The findings are based on records from more than 600,000 Danish women who were pregnant between 2004 and 2011. Of those women, about 0.3 percent received prescriptions for ondansetron. About half had nausea and vomiting severe enough that they had been hospitalized.

Overall, there was no evidence that the medication increased the risks of miscarriage, stillbirth, preterm delivery or major birth defects, according to the researchers, led by Dr. Bjorn Pasternak of the Statens Serum Institute in Copenhagen.

Of women given the morning-sickness drug in the first trimester, for example, just over 1 percent had a miscarriage, versus almost 4 percent of women who did not take the medication. And in both groups, 3 percent of moms had a baby with a major birth defect, such as a heart defect or malformations of the brain or spine, including spina bifida.

The study, which was funded by the Danish Medical Research Council, has its limits, Chambers said. It is observational, meaning it relied on women's medical records and looked for correlations between ondansetron prescriptions and risks to the developing fetus.

That's not enough to prove no risks exist, Chambers noted.

The researchers did account for other factors in a healthy pregnancy, such as the women's age and income and whether they smoked. But they couldn't factor in everything that affects pregnancy outcomes, Chambers said.

Dr. Jennifer Wu, an obstetrician/gynecologist at Lenox Hill Hospital in New York City, agreed. "It's an observational study, but that's what we have to go on," she said.

The best kinds of studies for showing a drug's benefits and risks are controlled clinical trials, where patients are randomly assigned to take a medication or not. It is generally considered unethical to include pregnant women in such studies, however, so doctors have to rely on studies like the current one -- records-based studies that look at whether pregnant women who used a given medication show any increased risks.

That's not ideal, but the new findings are reassuring, Wu said.

"This is a drug we've been using for a while," she said. "It can help keep women out of the hospital, and help keep them functioning on a day-to-day basis." For some women, Wu said, nausea and vomiting can be so severe that they can't get out of bed.

It's estimated that more than half of all pregnant women suffer from morning sickness. Usually, women can manage it without medication by, for example, eating smaller meals throughout the day, avoiding spicy foods and steering clear of strong smells that nauseate them.

But for some women, the problem is debilitating, and a small percentage develop hyperemesis, where a woman cannot keep any food down and she begins to lose weight.

Ondansetron fights nausea by lowering activity in the hormone serotonin. In the United States, it's the most commonly prescribed anti-nausea drug, and it is officially approved to treat nausea from cancer chemotherapy, radiation therapy and surgery. Its use against morning sickness has been based on only limited safety data.

"This study is reassuring in that it's a large database," Chambers said. "It supports this as an option for women."

The drug can have side effects for expectant moms. This study did not look at that, but in general the most common ones include constipation, dizziness, fatigue and headache.

According to the American College of Obstetricians and Gynecologists, some other options for severe morning sickness include vitamin B6, possibly along with a drug called doxylamine, which is found in over-the-counter sleep aids.

More information

Learn more about morning sickness from the American Pregnancy Association.

SOURCES: Christina Chambers, Ph.D., M.P.H., co-director, Center for Promotion of Maternal Health and Infant Development, University of California, San Diego; Jennifer Wu, M.D., Lenox Hill Hospital, New York City; Feb. 28, 2013, New England Journal of Medicine

Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Tree nut consumption associated with lower body weight and lower prevalence of health risks
2. Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks
3. Researchers determine vitamin D blood level for reducing major medical risks in older adults
4. Self-Managing COPD Might Pose Risks, Study Suggests
5. Benefits of Widespread Statin Use Outweigh Risks: Study
6. HRT Update: Therapy May Reduce Fractures, Boost Some Risks
7. Could Bloodletting Ease Heart Risks for the Obese?
8. Graphic warning labels improve smokers recall of warning and health risks related to smoking
9. Study Ties Kids Allergy Risks to Antibacterials, Preservatives
10. Antibodies from rabbits reduce risks associated with
11. Antibodies from rabbits reduce risks associated with unrelated donor stem cell transplantation
Post Your Comments:
Related Image:
No Risks to Pregnancy Seen With Morning Sickness Drug
(Date:11/30/2015)... ... November 30, 2015 , ... It’s inevitable that everyone ... member, close friend, or animal pass away, death lives among us. It is your ... Coming from a family of 11 children, author T Sky understands that she may ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... announce the speakers for “Value-Based Payer-Provider Partnerships: Three Case Studies,” an upcoming ... value-based care arrangements: Essentia Health and UCare, MissionPoint Health Partners, and Intel ...
(Date:11/30/2015)... IL (PRWEB) , ... November 30, 2015 , ... The ... an emerging pharmaceutical company. Because it is so important to this key industry segment, ... Factors in your IND Filing” on December 4th at 11am EST. , Federal law ...
(Date:11/30/2015)... ... November 30, 2015 , ... Insightra Medical, Inc. ... Surgical Mesh technology for soft tissue repair in the US via Insightra’s national ... resorbable surgical mesh intended to support and reinforce soft tissue for 6-9 months ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... & Laser Center is one of a select few plastic surgeons in the ... non-surgical fat removal. , SculpSure™ is the world’s first heat-induced laser treatment for ...
Breaking Medicine News(10 mins):
(Date:11/29/2015)... Iowa , Nov. 29, 2015 ... ultrasound guidance technology at the Radiological Society of ... in Chicago November 29 ... system is designed to offer customers unrivaled versatility, ... --> ...
(Date:11/27/2015)... 27, 2015 Ein neuer ... Krebs.   --> Ein neuer Kombinationsansatz ...   --> Ein neuer Kombinationsansatz ...   Clinical Cancer Research vom ... Cancer Research vom 6. November 2015 berichtet. ...
(Date:11/26/2015)... PUNE, India , November ... --> ... / personal emergency response system ... grow steadily for 5 years ... growing region expected to see ...
Breaking Medicine Technology: